Your browser doesn't support javascript.
loading
Principles and procedures for implementation of ICH M7 recommended (Q)SAR analyses.
Amberg, Alexander; Beilke, Lisa; Bercu, Joel; Bower, Dave; Brigo, Alessandro; Cross, Kevin P; Custer, Laura; Dobo, Krista; Dowdy, Eric; Ford, Kevin A; Glowienke, Susanne; Van Gompel, Jacky; Harvey, James; Hasselgren, Catrin; Honma, Masamitsu; Jolly, Robert; Kemper, Raymond; Kenyon, Michelle; Kruhlak, Naomi; Leavitt, Penny; Miller, Scott; Muster, Wolfgang; Nicolette, John; Plaper, Andreja; Powley, Mark; Quigley, Donald P; Reddy, M Vijayaraj; Spirkl, Hans-Peter; Stavitskaya, Lidiya; Teasdale, Andrew; Weiner, Sandy; Welch, Dennie S; White, Angela; Wichard, Joerg; Myatt, Glenn J.
Afiliación
  • Amberg A; Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.
  • Beilke L; Toxicology Solutions, San Diego, CA, USA.
  • Bercu J; Gilead, Foster City, CA, USA.
  • Bower D; Leadscope, Columbus, OH, USA.
  • Brigo A; Roche Pharmaceutical Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland.
  • Cross KP; Leadscope, Columbus, OH, USA.
  • Custer L; Bristol-Myers Squibb, New Brunswick, NJ, USA.
  • Dobo K; Pfizer, Groton, CT, USA.
  • Dowdy E; Gilead, Foster City, CA, USA.
  • Ford KA; Genentech, South San Francisco, USA.
  • Glowienke S; Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Van Gompel J; Janssen, Beerse, Belgium.
  • Harvey J; GlaxoSmithKline, Ware, Herts, UK.
  • Hasselgren C; Leadscope, Columbus, OH, USA.
  • Honma M; National Institute of Health Sciences, Tokyo, Japan.
  • Jolly R; Eli Lilly and Company, Indianapolis, IN, USA.
  • Kemper R; Vertex, Boston, MA, USA.
  • Kenyon M; Pfizer, Groton, CT, USA.
  • Kruhlak N; FDA Center for Drug Evaluation and Research, Silver Spring, MD, USA.
  • Leavitt P; Bristol-Myers Squibb, New Brunswick, NJ, USA.
  • Miller S; Leadscope, Columbus, OH, USA.
  • Muster W; Roche Pharmaceutical Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland.
  • Nicolette J; AbbVie Inc., North Chicago, IL, USA.
  • Plaper A; KRKA, Novo Mesto, Slovenia.
  • Powley M; FDA Center for Drug Evaluation and Research, Silver Spring, MD, USA.
  • Quigley DP; Leadscope, Columbus, OH, USA.
  • Reddy MV; Merck Research Laboratories, West Point, PA, USA.
  • Spirkl HP; Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.
  • Stavitskaya L; FDA Center for Drug Evaluation and Research, Silver Spring, MD, USA.
  • Teasdale A; AstraZeneca, Macclesfield, Cheshire, UK.
  • Weiner S; Janssen, Spring House, PA, USA.
  • Welch DS; AbbVie Inc., North Chicago, IL, USA.
  • White A; GlaxoSmithKline, Ware, Herts, UK.
  • Wichard J; Bayer HealthCare, Berlin, Germany.
  • Myatt GJ; Leadscope, Columbus, OH, USA. Electronic address: gmyatt@leadscope.com.
Regul Toxicol Pharmacol ; 77: 13-24, 2016 Jun.
Article en En | MEDLINE | ID: mdl-26877192
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Toxicología / Daño del ADN / Pruebas de Carcinogenicidad / Mutagénesis / Minería de Datos / Pruebas de Mutagenicidad / Mutágenos Tipo de estudio: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Regul Toxicol Pharmacol Año: 2016 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Toxicología / Daño del ADN / Pruebas de Carcinogenicidad / Mutagénesis / Minería de Datos / Pruebas de Mutagenicidad / Mutágenos Tipo de estudio: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Regul Toxicol Pharmacol Año: 2016 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Países Bajos